Nemaura Medical Inc. announced that it has commenced patient studies of its proprietary metabolic health program, Miboko, with the National Health Service (NHS) in the United Kingdom. Miboko, is the first metabolic tracking program to integrate a non-invasive glucose sensor with a lifestyle app that includes recording of food and drink, educational content, and an analytics platform. The program gives the user a metabolic score based on diet, exercise, and the user's individual glucose response to their food intake.

Users are given personalized recommendations to help them reduce weight, avoid serious health issues, such as heart disease and diabetes, and enjoy a better quality of life. The partnership with the UK's NHS is through medical centers that partner with the NHS National Institute for Health and Care Research (NIHR) to gather information that helps change and save lives. Miboko is expected to be available without prescription and is recommended for use by those wishing to lose weight.

The program will be offered to employers and insurers, as well as direct to consumers. In the U.S. alone, the program will be relevant to over 80 million people with prediabetes as well as to people with obesity. Significantly, Miboko will also be used by people who wish to embark on a diet program, of which a significant number will have tried alternative diet plans.

Miboko complements the BEATdiabetes program that is being commercialized for people with type 2 diabetes in the U.S. through strategic alliances, such as the one the Company announced previously with Eversana.